AstraZeneca Faces Sanctions In Seroquel MDL

Law360, New York (August 21, 2007, 12:00 AM EDT) -- The Florida court overseeing multidistrict products liability litigation over AstraZeneca LP's anti-psychotic drug Seroquel has ruled that the pharmaceutical company engaged in sanctionable conduct, granting in part a motion that accused the drug company of failing to comply with discovery obligations.

U.S. Magistrate Judge David A. Baker on Tuesday signed off on a 28-page order, finding that sanctions against AstraZeneca were warranted, and that AstraZeneca had been “purposefully sluggish” in making effective production to the plaintiffs.

Because the court had insisted on a tight schedule, “this...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.